OBJECTIVES: The objective of this study was to analyze the influence and development of 13 HTA bodies in select Emerging Markets. METHODS: This study examined 13 HTA bodies in Latin America (Argentina, Brazil, Colombia, and Mexico), Asia (Korea, Taiwan, China, Singapore, Malaysia, and Thailand), Africa (South Africa), Middle East (Saudi Arabia), as well as Central and Eastern Europe (Turkey). The countries were selected based on the diversity associated with the HTA evaluation process, and were assessed for their review timeline, influence on the pricing and reimbursement process, and anticipated future developments as indicated from their websites and other publications. RESULTS: Among the 13 selected HTA bodies, five countries (KOR, TWN, BRA, TUR, and ARG) have a defined review timeline; assessment outcomes will generally become available within a 1-year of submission. However, a standard timeline has yet to be defined for the rest of the countries. Four countries (KOR, TWN, BRA, and MEX) have formal HTA bodies, and assessments are mandatory in the pricing and reimbursement process. In other six countries (SGP, ARG, COL, THA, SAU, and TUR), HTA assessments may be considered in the pricing and reimbursement evaluation. For CHN / MYS / ZAF, although an HTA body is under development, it does not currently have any impact on the reimbursement decision-making. For future HTA developments, the focus remains on scope expansion, capability building, and international collaboration. CONCLUSIONS: Emerging markets have developed or are in the process of developing HTAs for the evaluation of formulary inclusion and as a method of cost containment. The HTA bodies in the selected emerging markets have varying impact over the pricing and reimbursement process. The ones with greater influence tend to have a defined review timeline and an HTA body that is a formal authority with a mandatory and / or influential assessment.